Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Video Abstracts
  • Reviews
    • View all reviews ...
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • Substance Use Disorders (Oct 2024)
    • Clonal Hematopoiesis (Oct 2024)
    • Sex Differences in Medicine (Sep 2024)
    • Vascular Malformations (Apr 2024)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Video Abstracts
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
Genetic repair. Bruce A. Sullenger, Series Editor
Ribozyme-mediated revision of RNA and DNA
Meredith B. Long, … , Bruce A. Sullenger, Jonghoe Byun
Meredith B. Long, … , Bruce A. Sullenger, Jonghoe Byun
Published August 1, 2003
Citation Information: J Clin Invest. 2003;112(3):312-318. https://doi.org/10.1172/JCI19386.
View: Text | PDF
Perspective Series

Genetic repair. Bruce A. Sullenger, Series Editor
Ribozyme-mediated revision of RNA and DNA

  • Text
  • PDF
Abstract

Authors

Meredith B. Long, J.P. Jones III, Bruce A. Sullenger, Jonghoe Byun

×

Figure 4

Options: View larger image (or click on image) Download as PowerPoint
Rational design and selection of retargeted introns using a mobility ass...
Rational design and selection of retargeted introns using a mobility assay in E. coli. (a) Rational design. Putative target sites may be searched in a gene of interest using the consensus sequence shown (N is any nucleotide). At positions where a subset of nucleotides is preferred by the LtrA protein, each preferred nucleotide is listed (in blue). The EBS of the intron is designed to base pair with the predicted IBS of the target (in red). Mobility is assessed in E. coli using donor and recipient plasmids as shown in b. (b) Selection of target sites. Retrohoming into the recipient plasmid activates expression of the promoterless tetracycline resistance gene (tetR, yellow box). The donor plasmid expresses the intron (L1.LtrB, in red) and associated protein (LtrA, in blue) following transformation into E. coli and isopropyl-β-D-thiogalactopyranoside (IPTG) induction of the T7lac promoter (PT7lac). The intron is flanked by exon sequences (E1 and E2) required for self-splicing. **A library of introns is generated by randomizing EBS sequences in the intron. IBS sequences in E1 are also randomized to facilitate forward splicing of the library of precursors. A T7 promoter (yellow arrowhead) is located in domain IV of the intron. Selectable markers on donor and recipient plasmids are shown (ampR, camR). Transcription termination signals prevent TetR expression in the absence of retrohoming. Retargeted introns are recovered from ampR, tetR colonies.

Copyright © 2025 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts